SCHEMBL1491918

SCHEMBL1491918

CCOC(=O)c1nn(-c2ccc(F)cc2)c(=O)c2c(N)scc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 1.00
▸ APP P05067 5/20 1.00
▸ MEN1 O00255 1/20 1.00
▸ KMT2A Q03164 1/20 1.00
▸ L3MBTL1 Q9Y468 1/20 1.00
▸ KDM4E B2RXH2 4/20 0.84
▸ ALDH1A1 P00352 4/20 0.84
▸ ALOX12 P18054 3/20 0.84
▸ ADORA1 P30542 12/20 0.83
▸ CASP1 P29466 2/20 0.81
▸ ALOX15 P16050 2/20 0.81
▸ HSD17B10 Q99714 2/20 0.81
▸ MAPK1 P28482 1/20 0.80
▸ CASP6 P55212 1/20 0.80
▸ APAF1 O14727 1/20 0.76
▸ CACNA1B Q00975 1/20 0.76
▸ APBA1 Q02410 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16379138 1.00 MAPT (1.00) MAPTAPPMEN1KMT2AL3MBTL1
SCHEMBL16379167 0.92 MAPT (1.00) MAPTAPPMEN1KMT2AL3MBTL1
SCHEMBL14660061 0.92 MAPT (0.88) MAPTAPPMEN1KMT2AL3MBTL1
SCHEMBL14659972 0.91 ADORA1 (1.00) MAPTAPPMEN1KMT2AL3MBTL1
SCHEMBL1491879 0.90 ADORA1 (1.00) MAPTAPPMEN1KMT2AL3MBTL1
SCHEMBL1491896 0.90 MAPT (0.84) MAPTAPPMEN1KMT2AL3MBTL1
SCHEMBL1491884 0.90 MAPT (1.00) MAPTAPPMEN1KMT2AL3MBTL1
SCHEMBL7885074 0.89 MAPT (1.00) MAPTAPPMEN1KMT2AL3MBTL1
SCHEMBL1491894 0.89 ADORA1 (1.00) MAPTAPPMEN1KMT2AL3MBTL1
SCHEMBL7877338 0.89 MAPT (0.88) MAPTAPPMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150004100-A1 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY GE HEALTHCARE LIMITED (GB) 2015-01-01 — — US disclosed
US-20150004100-A1 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY GE HEALTHCARE LIMITED (GB) 2015-01-01 — — US disclosed
WO-2013090497-A1 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY GE HEALTHCARE LIMITED (GB) 2013-06-20 — — WO disclosed
US-20130029983-A1 AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2013-01-31 — — US disclosed
WO-2011037985-A1 AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2011-03-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150004100-A1 HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY MAPT, NAT1, APP MAPT 1/4885APP 3/4885MEN1 3569/4885
US-20130029983-A1 AMINOTHIENOPYRIDAZINE INHIBITORS OF TAU ASSEMBLY MAPT, PSEN1, PSEN2 MAPT 1/4885APP 6/4885MEN1 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback